Gossamer Bio, Inc. (GOSS)
 NASDAQ: GOSS · Real-Time Price · USD
 2.475
 +0.055 (2.27%)
  Oct 31, 2025, 1:08 PM EDT - Market open
Gossamer Bio Revenue
Gossamer Bio had revenue of $11.49M in the quarter ending June 30, 2025, a decrease of -88.01%. This brings the company's revenue in the last twelve months to $40.24M, down -58.02% year-over-year. In the year 2024, Gossamer Bio had annual revenue of $114.70M.
Revenue (ttm) 
 $40.24M
Revenue Growth 
 -58.02%
P/S Ratio 
 13.64
Revenue / Employee 
 $277,497
Employees 
 145
Market Cap 
568.95M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 114.70M | - | - | 
| Dec 31, 2023 | - | - | - | 
| Dec 31, 2022 | - | - | - | 
| Dec 31, 2021 | - | - | - | 
| Dec 31, 2020 | - | - | - | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 64.24B | 
| Eli Lilly and Company | 59.42B | 
| AbbVie | 58.33B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Novo Nordisk | 49.11B | 
GOSS News
- 5 weeks ago - Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital - PRNewsWire
- 5 weeks ago - Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension - Business Wire
- 5 weeks ago - Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025 - Business Wire
- 7 weeks ago - Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 7 weeks ago - Gossamer Bio: Bullish Ahead Of Seralutinib's Phase 3 Readout - Seeking Alpha
- 2 months ago - Gossamer Bio to Present at Upcoming Investor Conferences - Business Wire
- 3 months ago - Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 4 months ago - Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH - Business Wire